Editas Medicine Inc. (EDIT)

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - R...

Gene-editing company Editas Medicine (EDIT -4.06%) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34%...

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago.

Editas Medicine (EDIT 2.50%), a small-cap biotech company, is up by 81% since January. But zooming out gives us a completely different picture.

Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

An updated edition of the June 27, 2025, article.

Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way...

Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatili...